<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545582</url>
  </required_header>
  <id_info>
    <org_study_id>C-05</org_study_id>
    <nct_id>NCT02545582</nct_id>
  </id_info>
  <brief_title>VITARIA Registry Study</brief_title>
  <official_title>VITARIA Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry will observe patients with symptomatic heart failure with implantable vagus&#xD;
      nerve stimulation to provide insights into safety and efficacy during clinical routine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational prospective clinical registry in patients with symptomatic heart failure and&#xD;
      implanted with the VITARIA System. Assessments will be made during 12 months of&#xD;
      post-titration chronic stimulation. The registry will collect patient- and device follow-up&#xD;
      data in clinical routine practice at baseline, 3, 6 and 12 months. Clinical routine safety of&#xD;
      the therapy will be assessed by the incidence of procedure and device-related events.&#xD;
      Clinical routine efficacy will be assessed by changes in cardiac function and heart failure&#xD;
      symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Sponsor decision&#xD;
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Serious and non-serious adverse events, according to ISO 14155</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LVEF</measure>
    <time_frame>12 months</time_frame>
    <description>Left ventricular ejection fraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LVESV</measure>
    <time_frame>12 months</time_frame>
    <description>Left ventricular end-systolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESV Index</measure>
    <time_frame>12 months</time_frame>
    <description>Left ventricular end-systolic volume index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class</measure>
    <time_frame>12 months</time_frame>
    <description>New York Heart Association classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Minnesota Living with Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Mean heart rate, 24-hour ambulatory ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>12 months</time_frame>
    <description>SDNN, 24-hour ambulatory ECG</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Therapy</arm_group_label>
    <description>Heart failure patients implanted with the VITARIA system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VITARIA System</intervention_name>
    <description>Implantable vagus nerve stimulator</description>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic heart failure, NYHA class II/III with LVEF≤40%&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and capable of providing informed consent according to national data privacy&#xD;
             regulations&#xD;
&#xD;
          2. Patients with NYHA class II/III&#xD;
&#xD;
          3. LVEF≤40% by imaging method such as echocardiography, radionuclide angiography, left&#xD;
             ventriculography, or cardiac magnetic resonance imaging, documented less than 12 weeks&#xD;
             before implantation of VITARIA system&#xD;
&#xD;
          4. Receiving optimal pharmacological heart failure therapy for at least 3 months&#xD;
&#xD;
          5. Recent implantation of the VITARIA system, prior to device activation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hospitalization for heart failure and/or required the use of Heart Failure intravenous&#xD;
             therapy in the past 30 days&#xD;
&#xD;
          2. Severe mitral and/or any aortic valve dysfunction&#xD;
&#xD;
          3. History of acute coronary syndrome (ACS) in the past 90 days&#xD;
&#xD;
          4. Stroke or transient ischemic attack (TIA) in the past 90 days&#xD;
&#xD;
          5. Coronary Artery Bypass Surgery (CABG) in the past 90 days&#xD;
&#xD;
          6. PCI in the past 90 days&#xD;
&#xD;
          7. Surgery for Valve replacement (Aortic or mitral valve) in the past 90 days&#xD;
&#xD;
          8. Left ventricular end diastolic diameter (LVEDD) &gt; 80 mm&#xD;
&#xD;
          9. Patients who have had a cardiac resynchronization therapy (CRT) device implanted and&#xD;
             have been actively treated with CRT for &lt; 12 months&#xD;
&#xD;
         10. Patients that are scheduled for CRT&#xD;
&#xD;
         11. Patients who are listed for heart transplant or expected to be candidates for heart&#xD;
             transplant&#xD;
&#xD;
         12. Patients on hemodialysis or peritoneal dialysis&#xD;
&#xD;
         13. Patients with diabetes (type I or type II) that is being medically treated for&#xD;
             autonomic or sensory neuropathy, or measured hemoglobin A1c (HbA1c) above 8.0% in the&#xD;
             past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRI GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRI GmbH</name>
      <address>
        <city>Munich</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

